Condition (MeSH)
Histiocytoma, Malignant Fibrous
ClinicalTrials.gov lists 91 trials for Histiocytoma, Malignant Fibrous or a narrower condition beneath it. European Organisation for Research and Treatment of Cancer - EORTC has the most among industry and government lead sponsors, with 15.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
91 of the 91 trials are tagged with Histiocytoma, Malignant Fibrous itself; the rest are tagged with a narrower condition beneath it.
When did Histiocytoma, Malignant Fibrous trials start? (32)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Not applicable
- Observational
Top of scale: 7
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2025 | 2 |
| 2024 | 4 |
| 2023 | 2 |
| 2022 | 3 |
| 2021 | 3 |
| 2020 | 7 |
| 2019 | 6 |
| 2018 | 3 |
| 2017 | 4 |
Showing 10 of 32 earlier years.
No forecast is made for this condition: it averages 3.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 10 trials still running at the 2026-10-09 snapshot; registered median of 44 months across 57 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Histiocytoma, Malignant Fibrous trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 16 |
| Phase 1/2 | 8 |
| Phase 2 | 44 |
| Phase 2/3 | 2 |
| Phase 3 | 11 |
| Not applicable | 6 |
| Observational | 4 |
How many Histiocytoma, Malignant Fibrous trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 5 |
| Recruiting | 10 |
| Active, not recruiting | 5 |
| Completed | 50 |
| Terminated | 9 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Histiocytoma, Malignant Fibrous trials? (7)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| European Organisation for Research and Treatment of Cancer - EORTC | 15 |
| National Cancer Institute (NCI) | 14 |
| Eli Lilly and Company | 2 |
| AbbVie | 1 |
| BioAtla, Inc. | 1 |
Showing 5 of 7 sponsors.
Which drugs are being tested for Histiocytoma, Malignant Fibrous? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| IPILIMUMAB | 6 |
| PEMBROLIZUMAB | 6 |
| NIVOLUMAB | 5 |
| Trabectedin | 3 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Doxorubicine | 21 |
| Ifosfamid | 12 |
| Radiation Therapy | 9 |
| Gemcitabine/Gemzar | 4 |
| Pegylated Liposomal Doxorubicin (PLD), Doxil | 3 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Histiocytoma, Malignant Fibrous trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Febrile neutropenia | 105 | 8 |
| Vomiting | 35 | 9 |
| Anemia | 31 | 8 |
| Abdominal pain | 28 | 10 |
| Fatigue | 25 | 10 |
Showing 5 of 10 adverse events.
Which publications cover Histiocytoma, Malignant Fibrous? (9)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Melorheostosis: A Review of the Literature and a Case Report. | Medicina (Kaunas, Lithuania) | 2023 | Yes |
| Angiomatoid fibrous histiocytoma: an expansion of the clinical and histological spectrum. | Pathology | 2014 | Yes |
| Angiomatoid fibrous histiocytoma: unusual sites and unusual morphology. | Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc | 2011 | Yes |
| Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. | Nature genetics | 2010 | Yes |
| EWSR1-CREB1 is the predominant gene fusion in angiomatoid fibrous histiocytoma. | Genes, chromosomes & cancer | 2007 | Yes |
Showing 5 of 9 publications.
Prevalence (9)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Undifferentiated pleomorphic sarcoma | Annual incidence | 1-9 / 1 000 000 | United States | US | Exact |
| Undifferentiated pleomorphic sarcoma | Annual incidence | 1-9 / 1 000 000 | United States | US | Exact |
| Undifferentiated pleomorphic sarcoma | Annual incidence | 1-9 / 1 000 000 | United States | US | Unspecified |
| Undifferentiated pleomorphic sarcoma | Annual incidence | 1-9 / 1 000 000 | Europe | Not stated | Exact |
| Undifferentiated pleomorphic sarcoma | Point prevalence | 1-9 / 100 000 | Europe | Not stated | Unspecified |
Showing 5 of 9 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Undifferentiated pleomorphic sarcoma | 2023 | Exact | Orphadata Science knowledge files, Product 1 |
| Undifferentiated pleomorphic sarcoma | 2023 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.